Press releases

CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU for patients with triple class refractory multiple myeloma

Regulatory

June 23, 2022

STOCKHOLM — June 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ann...

Read more

Annual General Meeting in Oncopeptides AB (publ)

May 25, 2022

STOCKHOLM — May 25, 2022 — The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given...

Read more

Oncopeptides publishes Q1 report 2022

Regulatory

May 4, 2022

STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publi...

Read more

Invitation to presentation of Q1 report

April 27, 2022

STOCKHOLM — April 27, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...

Read more

Oncopeptides publishes the 2021 Annual Report

Regulatory

April 21, 2022

STOCKHOLM — April 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...

Read more

Number of shares and votes in Oncopeptides

Regulatory

March 31, 2022

STOCKHOLM — March 31, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today an...

Read more

Oncopeptides publishes year-end report 2021

Regulatory

February 17, 2022

STOCKHOLM — February 17, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, has today publ...

Read more

Invitation to presentation of 2021 year-end results

February 14, 2022

STOCKHOLM — February 14, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish i...

Read more

Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US – no intent to market in the US at this time

Regulatory

January 21, 2022

STOCKHOLM — January 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...

Read more

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

January 13, 2022

STOCKHOLM — January 13, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...

Read more

Oncopeptides announces year-end cash 2021

Regulatory

January 5, 2022

STOCKHOLM — January 5, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today a...

Read more